Format

Send to

Choose Destination
JCO Clin Cancer Inform. 2019 May;3:1-6. doi: 10.1200/CCI.18.00128.

Clinician Report of Oral Oncolytic Symptoms and Adherence Obtained via a Patient-Reported Outcome Measure (PROM).

Author information

1
1 University of Michigan, Ann Arbor, MI.
2
2 University of Michigan College of Pharmacy, Ann Arbor, MI.
3
3 Michigan Oncology Quality Consortium, Ann Arbor, MI.
4
4 IHA Hematology Oncology Consultants, Ypsilanti, MI.

Abstract

PURPOSE:

Patient-reported outcome measures (PROMs) for symptom monitoring during cancer therapy have been shown to have a positive impact on outcomes. These findings have primarily been shown for patients receiving intravenous chemotherapy. In addition, there is known discordance between physician reporting of symptoms and patient self-report. This initiative sought to describe patient-reported symptom burden and medication adherence and to indicate the degree of PROM results being discussed with the provider as indicated by documentation in the medical record for patients taking oral oncolytic therapy.

METHODS:

The Michigan Oncology Quality Consortium (MOQC) PROM, which included symptom ratings, medication adherence, and patient confidence in self-management, was completed during outpatient visits and compared with corresponding data documented in the electronic medical record (EMR).

RESULTS:

There were 82 completed PROMs. Approximately half included at least one symptom rated as severe (46%). Sixty-five percent of reported severe symptoms were documented in the EMR. Patient-reported moderate-to-severe pain was most likely to be documented in the EMR (100%), whereas patient-reported moderate-to-severe depression and anxiety were least likely to be documented (21%). Of the total symptoms documented, grading of symptom severity matched that of the patients' own report for 11% of severe symptoms. Adherence to oral oncolytics was excellent for 63% of patients, and patient adherence was documented in 7% of provider notes.

CONCLUSION:

Patients frequently reported moderate-to-severe symptoms, and approximately 40% of patients reported nonadherence. Clinician report (documented in the EMR) of the patient symptom burden, symptom severity, and adherence to oral oncolytic therapy was not consistent with the patients' self-report. Use of a PROM for patients taking oral oncolytics has the opportunity to improve symptom management and medication adherence.

PMID:
31100014
DOI:
10.1200/CCI.18.00128
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center